Deep sequencing reveals a novel miR-22 regulatory network with therapeutic potential in rhabdomyosarcoma

Francesca Bersani, Marcello Francesco Lingua, Deborah Morena, Valentina Foglizzo, Silvia Miretti, Letizia Lanzetti, Giovanna Carrà, Alessandro Morotti, Ugo Ala, Paolo Provero, Roberto Chiarle, Samuel Singer, Marc Ladanyi, Thomas Tuschl, Carola Ponzetto, Riccardo Taulli

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

Current therapeutic options for the pediatric cancer rhabdomyosarcoma have not improved significantly, especially for metastatic rhabdomyosarcoma. In the current work, we performed a deep miRNA profiling of the three major human rhabdomyosarcoma subtypes, along with cell lines and normal muscle, to identify novel molecular circuits with therapeutic potential. The signature we determined could discriminate rhabdomyosarcoma from muscle, revealing a subset of muscle-enriched miRNA (myomiR), including miR-22, which was strongly underexpressed in tumors. miR-22 was physiologically induced during normal myogenic differentiation and was transcriptionally regulated by MyoD, confirming its identity as a myomiR. Once introduced into rhabdomyosarcoma cells, miR-22 decreased cell proliferation, anchorage-independent growth, invasiveness, and promoted apoptosis. Moreover, restoring miR-22 expression blocked tumor growth and prevented tumor dissemination in vivo. Gene expression profiling analysis of miR-22-expressing cells suggested TACC1 and RAB5B as possible direct miR-22 targets. Accordingly, loss- and gain-of-function experiments defined the biological relevance of these genes in rhabdomyosarcoma pathogenesis. Finally, we demonstrated the ability of miR-22 to intercept and overcome the intrinsic resistance to MEK inhibition based on ERBB3 upregulation. Overall, our results identified a novel miR-22 regulatory network with critical therapeutic implications in rhabdomyosarcoma.

Original languageEnglish
Pages (from-to)6095-6106
Number of pages12
JournalCancer Research
Volume76
Issue number20
DOIs
Publication statusPublished - Oct 15 2016

Fingerprint

High-Throughput Nucleotide Sequencing
Rhabdomyosarcoma
MicroRNAs
Muscles
Therapeutics
Neoplasms
Mitogen-Activated Protein Kinase Kinases
Gene Expression Profiling
Growth
Up-Regulation
Cell Proliferation
Pediatrics
Apoptosis
Cell Line
Genes

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Deep sequencing reveals a novel miR-22 regulatory network with therapeutic potential in rhabdomyosarcoma. / Bersani, Francesca; Lingua, Marcello Francesco; Morena, Deborah; Foglizzo, Valentina; Miretti, Silvia; Lanzetti, Letizia; Carrà, Giovanna; Morotti, Alessandro; Ala, Ugo; Provero, Paolo; Chiarle, Roberto; Singer, Samuel; Ladanyi, Marc; Tuschl, Thomas; Ponzetto, Carola; Taulli, Riccardo.

In: Cancer Research, Vol. 76, No. 20, 15.10.2016, p. 6095-6106.

Research output: Contribution to journalArticle

Bersani, F, Lingua, MF, Morena, D, Foglizzo, V, Miretti, S, Lanzetti, L, Carrà, G, Morotti, A, Ala, U, Provero, P, Chiarle, R, Singer, S, Ladanyi, M, Tuschl, T, Ponzetto, C & Taulli, R 2016, 'Deep sequencing reveals a novel miR-22 regulatory network with therapeutic potential in rhabdomyosarcoma', Cancer Research, vol. 76, no. 20, pp. 6095-6106. https://doi.org/10.1158/0008-5472.CAN-16-0709
Bersani, Francesca ; Lingua, Marcello Francesco ; Morena, Deborah ; Foglizzo, Valentina ; Miretti, Silvia ; Lanzetti, Letizia ; Carrà, Giovanna ; Morotti, Alessandro ; Ala, Ugo ; Provero, Paolo ; Chiarle, Roberto ; Singer, Samuel ; Ladanyi, Marc ; Tuschl, Thomas ; Ponzetto, Carola ; Taulli, Riccardo. / Deep sequencing reveals a novel miR-22 regulatory network with therapeutic potential in rhabdomyosarcoma. In: Cancer Research. 2016 ; Vol. 76, No. 20. pp. 6095-6106.
@article{f5db8e1e10d54e89b2e11b350c6abfb5,
title = "Deep sequencing reveals a novel miR-22 regulatory network with therapeutic potential in rhabdomyosarcoma",
abstract = "Current therapeutic options for the pediatric cancer rhabdomyosarcoma have not improved significantly, especially for metastatic rhabdomyosarcoma. In the current work, we performed a deep miRNA profiling of the three major human rhabdomyosarcoma subtypes, along with cell lines and normal muscle, to identify novel molecular circuits with therapeutic potential. The signature we determined could discriminate rhabdomyosarcoma from muscle, revealing a subset of muscle-enriched miRNA (myomiR), including miR-22, which was strongly underexpressed in tumors. miR-22 was physiologically induced during normal myogenic differentiation and was transcriptionally regulated by MyoD, confirming its identity as a myomiR. Once introduced into rhabdomyosarcoma cells, miR-22 decreased cell proliferation, anchorage-independent growth, invasiveness, and promoted apoptosis. Moreover, restoring miR-22 expression blocked tumor growth and prevented tumor dissemination in vivo. Gene expression profiling analysis of miR-22-expressing cells suggested TACC1 and RAB5B as possible direct miR-22 targets. Accordingly, loss- and gain-of-function experiments defined the biological relevance of these genes in rhabdomyosarcoma pathogenesis. Finally, we demonstrated the ability of miR-22 to intercept and overcome the intrinsic resistance to MEK inhibition based on ERBB3 upregulation. Overall, our results identified a novel miR-22 regulatory network with critical therapeutic implications in rhabdomyosarcoma.",
author = "Francesca Bersani and Lingua, {Marcello Francesco} and Deborah Morena and Valentina Foglizzo and Silvia Miretti and Letizia Lanzetti and Giovanna Carr{\`a} and Alessandro Morotti and Ugo Ala and Paolo Provero and Roberto Chiarle and Samuel Singer and Marc Ladanyi and Thomas Tuschl and Carola Ponzetto and Riccardo Taulli",
year = "2016",
month = "10",
day = "15",
doi = "10.1158/0008-5472.CAN-16-0709",
language = "English",
volume = "76",
pages = "6095--6106",
journal = "Journal of Cancer Research",
issn = "0008-5472",
publisher = "American Association for Cancer Research Inc.",
number = "20",

}

TY - JOUR

T1 - Deep sequencing reveals a novel miR-22 regulatory network with therapeutic potential in rhabdomyosarcoma

AU - Bersani, Francesca

AU - Lingua, Marcello Francesco

AU - Morena, Deborah

AU - Foglizzo, Valentina

AU - Miretti, Silvia

AU - Lanzetti, Letizia

AU - Carrà, Giovanna

AU - Morotti, Alessandro

AU - Ala, Ugo

AU - Provero, Paolo

AU - Chiarle, Roberto

AU - Singer, Samuel

AU - Ladanyi, Marc

AU - Tuschl, Thomas

AU - Ponzetto, Carola

AU - Taulli, Riccardo

PY - 2016/10/15

Y1 - 2016/10/15

N2 - Current therapeutic options for the pediatric cancer rhabdomyosarcoma have not improved significantly, especially for metastatic rhabdomyosarcoma. In the current work, we performed a deep miRNA profiling of the three major human rhabdomyosarcoma subtypes, along with cell lines and normal muscle, to identify novel molecular circuits with therapeutic potential. The signature we determined could discriminate rhabdomyosarcoma from muscle, revealing a subset of muscle-enriched miRNA (myomiR), including miR-22, which was strongly underexpressed in tumors. miR-22 was physiologically induced during normal myogenic differentiation and was transcriptionally regulated by MyoD, confirming its identity as a myomiR. Once introduced into rhabdomyosarcoma cells, miR-22 decreased cell proliferation, anchorage-independent growth, invasiveness, and promoted apoptosis. Moreover, restoring miR-22 expression blocked tumor growth and prevented tumor dissemination in vivo. Gene expression profiling analysis of miR-22-expressing cells suggested TACC1 and RAB5B as possible direct miR-22 targets. Accordingly, loss- and gain-of-function experiments defined the biological relevance of these genes in rhabdomyosarcoma pathogenesis. Finally, we demonstrated the ability of miR-22 to intercept and overcome the intrinsic resistance to MEK inhibition based on ERBB3 upregulation. Overall, our results identified a novel miR-22 regulatory network with critical therapeutic implications in rhabdomyosarcoma.

AB - Current therapeutic options for the pediatric cancer rhabdomyosarcoma have not improved significantly, especially for metastatic rhabdomyosarcoma. In the current work, we performed a deep miRNA profiling of the three major human rhabdomyosarcoma subtypes, along with cell lines and normal muscle, to identify novel molecular circuits with therapeutic potential. The signature we determined could discriminate rhabdomyosarcoma from muscle, revealing a subset of muscle-enriched miRNA (myomiR), including miR-22, which was strongly underexpressed in tumors. miR-22 was physiologically induced during normal myogenic differentiation and was transcriptionally regulated by MyoD, confirming its identity as a myomiR. Once introduced into rhabdomyosarcoma cells, miR-22 decreased cell proliferation, anchorage-independent growth, invasiveness, and promoted apoptosis. Moreover, restoring miR-22 expression blocked tumor growth and prevented tumor dissemination in vivo. Gene expression profiling analysis of miR-22-expressing cells suggested TACC1 and RAB5B as possible direct miR-22 targets. Accordingly, loss- and gain-of-function experiments defined the biological relevance of these genes in rhabdomyosarcoma pathogenesis. Finally, we demonstrated the ability of miR-22 to intercept and overcome the intrinsic resistance to MEK inhibition based on ERBB3 upregulation. Overall, our results identified a novel miR-22 regulatory network with critical therapeutic implications in rhabdomyosarcoma.

UR - http://www.scopus.com/inward/record.url?scp=84991740158&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84991740158&partnerID=8YFLogxK

U2 - 10.1158/0008-5472.CAN-16-0709

DO - 10.1158/0008-5472.CAN-16-0709

M3 - Article

AN - SCOPUS:84991740158

VL - 76

SP - 6095

EP - 6106

JO - Journal of Cancer Research

JF - Journal of Cancer Research

SN - 0008-5472

IS - 20

ER -